#United States #New York #Securities Fraud #Pomerantz LLP #Capricor Therapeutics

Pomerantz Law Firm Investigates Potential Securities Fraud on Behalf of Capricor Therapeutics Investors

On September 3, 2025, the notable Pomerantz Law Firm announced they are conducting an investigation into purported fraudulent practices concerning Capricor Therapeutics, Inc. (NASDAQ: CAPR). The inquiry addresses whether the company and some of its executives have engaged in unlawful business conduct that may have misled investors.

Background on Capricor Therapeutics

Capricor Therapeutics is a biotechnology firm focused on pioneering cell therapies for serious medical conditions, such as Duchenne muscular dystrophy (DMD). On May 5, 2025, the company released a press statement regarding the progression of its Biologics License Application (BLA) for deramiocel, a groundbreaking therapy aimed at treating DMD cardiomyopathy. In this communication, the firm indicated that the FDA had planned to conduct an advisory committee meeting regarding the BLA.

This announcement triggered an alarming response in the stock market, with Capricor's share price plunging by $3.00, or 29.13%, to a closing price of $7.30 on May 6, 2025. Investors began to express concerns about the potential implications of the advisory committee meeting.

However, the situation deteriorated further. On June 20, 2025, a report by STAT revealed that the newly appointed head of the corresponding FDA division had canceled the planned advisory meeting due to concerns regarding the efficacy and safety of deramiocel. Following this revelation, Capricor's stock price experienced another significant drop, falling $3.68, equivalent to 30.82%, and closing at $8.26 per share on the same day.

Invitation for Affected Investors

In light of these developments, Pomerantz LLP is reaching out to investors who may have suffered losses in connection with Capricor's recent market fluctuations. The firm is encouraging these individuals to reach out to attorney Danielle Peyton for further assistance. Contact can be made via phone at 646-581-9980, ext. 7980, or through email at [email protected].

About Pomerantz LLP

Established over 85 years ago by the late Abraham L. Pomerantz, widely regarded as a pioneer in class action litigation, Pomerantz LLP has gained a formidable reputation for representing victims of securities fraud. The firm's extensive track record includes recovering significant damages on behalf of class members impacted by corporate wrongdoing. With offices in key cities like New York, Chicago, and Los Angeles, the firm remains dedicated to advocating for investors’ rights and bringing corporate misconduct to light.

Investors should be aware that prior outcomes do not guarantee similar results in ongoing or future investigations. For more information on this case or to join the class action, individuals can visit www.pomlaw.com.

Conclusion

The unfolding situation surrounding Capricor Therapeutics serves as a stark reminder of the risks involved in investing within the volatile biotech sector. As developments progress, the Pomerantz Law Firm will continue to delve into this matter and keep investors informed. Those affected are advised to stay vigilant and consider seeking legal guidance to protect their financial interests.